Absci (ABSI) Revenue Growth (1y) (2021 - 2026)
Absci (ABSI) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 96.43% |
| 10 | Absci | 1.18 Bn | 1.06 Bn | - | -81.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.76% |
| Dec 31, 2025 | -2.26% |
| Sep 30, 2025 | -77.78% |
| Jun 30, 2025 | -53.31% |
| Mar 31, 2025 | 31.29% |
| Dec 31, 2024 | 96.75% |
| Sep 30, 2024 | 128.63% |
| Jun 30, 2024 | -62.28% |
| Mar 31, 2024 | -29.24% |
| Dec 31, 2023 | -0.29% |
| Sep 30, 2023 | 103.84% |
| Jun 30, 2023 | 236.03% |
| Mar 31, 2023 | 247.67% |
| Dec 31, 2022 | 115.77% |
| Sep 30, 2022 | 144.97% |
| Jun 30, 2022 | 37.64% |
| Mar 31, 2022 | -65.66% |
| Dec 31, 2021 | -153.34% |
| Sep 30, 2021 | -83.73% |
| Jun 30, 2021 | 29.08% |